ICD G11.1ORPHA:95FRDA

Friedreich Ataxia

Friedreich ataxia is a progressive genetic condition that damages the nervous system and heart, causing loss of coordination, balance problems, and heart disease. It is the most common inherited ataxia. Symptoms usually begin in childhood or adolescence. The first approved treatment, omaveloxolone, reached approval in 2023.

533
Articles
93
Trials (13 AU)
Updated
25 March 2026
Loading...

Common Questions

What is Friedreich Ataxia?

Friedreich ataxia is a progressive genetic condition that damages the nervous system and heart, causing loss of coordination, balance problems, and heart disease. It is the most common inherited ataxia. Symptoms usually begin in childhood or adolescence. The first approved treatment, omaveloxolone, reached approval in 2023.

How many clinical trials are available for Friedreich Ataxia?

RareWays currently indexes 93 clinical trials for Friedreich Ataxia, of which 17 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.

Where does the research data for Friedreich Ataxia come from?

RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.

Get research updates

Monthly email when new findings are published for Friedreich Ataxia.

No spam. Unsubscribe any time. Not medical advice.

This information is for general awareness only.

For guidance specific to your situation, please speak with your healthcare team.